Royal Bank Of Canada Xilio Therapeutics, Inc. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.9 - $1.53 $150 - $255	-167 Reduced 31.33%	366 $0
Q1 2024 Nov 05, 2024	BUY	$0.55 - $1.08 $91 - $180	167 Added 45.63%	533 $0
Q1 2024 May 15, 2024	BUY	$0.55 - $1.08 $35 - $70	65 Added 13.89%	533 $0
Q4 2023 Feb 14, 2024	BUY	$0.5 - $2.5 $59 - $295	118 Added 33.71%	468 $0
Q3 2023 Nov 14, 2023	SELL	$2.11 - $2.9 $2,588 - $3,558	-1,227 Reduced 77.81%	350 $0
Q2 2023 Aug 14, 2023	BUY	$2.55 - $3.46 $2,157 - $2,927	846 Added 115.73%	1,577 $4,000
Q1 2023 May 15, 2023	BUY	$2.66 - $4.28 $1,944 - $3,128	731 New	731 $2,000
Q2 2022 Aug 15, 2022	SELL	$2.08 - $7.2 $977 - $3,384	-470 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$6.63 - $16.05 $7,392 - $17,895	-1,115 Reduced 70.35%	470 $3,000
Q4 2021 Feb 14, 2022	BUY	$9.69 - $25.11 $15,358 - $39,799	1,585 New	1,585 $25,000

14M

Ticker XLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,471,600
Market Cap $25.8M
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.